scyllo-Inositol promotes robust mutant Huntingtin protein degradation

Huntington disease is characterized by neuronal aggregates and inclusions containing polyglutamine-expanded Huntingtin protein and peptide fragments (polyQ-Htt). We have used an established cell-based assay employing a PC12 cell line overexpressing truncated exon 1 of Htt with a 103-residue polyQ expansion that yields polyQ-Htt aggregates to investigate the fate of polyQ-Htt-drug complexes. scyllo-Inositol is an endogenous inositol stereoisomer known to inhibit accumulation and toxicity of the Amyloid-β peptide and α-synuclein. In light of these properties, we investigated the effect of scyllo-inositol on polyQ-Htt accumulation. We show that scyllo-inositol lowered the number of visible polyQ-Htt aggregates and robustly decreased polyQ-Htt protein abundance without concomitant cellular toxicity. We found that scyllo-inositol-induced polyQ-Htt reduction was by rescue of degradation pathways mediated by the lysosome and by the Proteasome but not autophagosomes. The rescue of degradation pathways was not a direct result of scyllo-inositol on the lysosome or Proteasome but due to scyllo-inositol-induced reduction in mutant polyQ-Htt protein levels.

Autophagy; Huntington Disease; Lysosomes; Neurodegenerative Diseases; Proteasome; huntingtin; scyllo-Inositol.